Differential regulation of Type 1 and Type 2 mouse eosinophil activation by apoptotic cells.
IFN-gamma
IL-4
allergy
apoptotic cells
eosinophils
inflammation
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
09
2022
accepted:
07
10
2022
entrez:
17
11
2022
pubmed:
18
11
2022
medline:
22
11
2022
Statut:
epublish
Résumé
Eosinophils are multifunctional, evolutionary conserved leukocytes that are involved in a plethora of responses ranging from regulation of tissue homeostasis, host defense and cancer. Although eosinophils have been studied mostly in the context of Type 2 inflammatory responses, it is now evident that they participate in Type 1 inflammatory responses and can respond to Type 1 cytokines such as IFN-γ. Notably, both Type 1- and Type 2 inflammatory environments are characterized by tissue damage and cell death. Collectively, this raises the possibility that eosinophils can interact with apoptotic cells, which can alter eosinophil activation in the inflammatory milieu. Herein, we demonstrate that eosinophils can bind and engulf apoptotic cells. We further show that exposure of eosinophils to apoptotic cells induces marked transcriptional changes in eosinophils, which polarize eosinophils towards an anti-inflammatory phenotype that is associated with wound healing and cell migration. Using an unbiased RNA sequencing approach, we demonstrate that apoptotic cells suppress the inflammatory responses of eosinophils that were activated with IFN-γ +
Identifiants
pubmed: 36389786
doi: 10.3389/fimmu.2022.1041660
pmc: PMC9662748
doi:
Substances chimiques
Cytokines
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1041660Informations de copyright
Copyright © 2022 Dolitzky, Hazut, Avlas, Grisaru-Tal, Itan, Zaffran, Levi-Schaffer, Gerlic and Munitz.
Déclaration de conflit d'intérêts
AM is a consultant for Glaxo Smith Kline, Astra Zeneca, Sanofi, Oravax, Sartorious and is an inventor of three patents owned by the Tel Aviv University. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor YT declared a shared parent affiliation with the authors IZ and F-LS at the time of review.
Références
Br J Pharmacol. 2008 Sep;155(2):152-69
pubmed: 18641677
Mayo Clin Proc. 2021 Oct;96(10):2694-2707
pubmed: 34538424
J Exp Med. 1998 Nov 16;188(10):1859-66
pubmed: 9815263
Annu Rev Immunol. 2006;24:147-74
pubmed: 16551246
Bioinformatics. 2018 Sep 1;34(17):i884-i890
pubmed: 30423086
J Leukoc Biol. 2018 May;103(5):885-895
pubmed: 29603355
Cell. 2007 Dec 14;131(6):1124-36
pubmed: 18083102
Mucosal Immunol. 2014 Mar;7(2):292-303
pubmed: 23820751
Nat Commun. 2014;5:3146
pubmed: 24477292
Front Immunol. 2018 Jan 18;9:22
pubmed: 29403501
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Cancer Immunol Res. 2019 Mar;7(3):388-400
pubmed: 30665890
Cell. 2019 Mar 7;176(6):1248-1264
pubmed: 30849371
PLoS One. 2013 Aug 02;8(8):e72772
pubmed: 23936544
Nat Rev Immunol. 2020 Apr;20(4):254-267
pubmed: 31822793
Blood. 2012 Mar 22;119(12):2799-809
pubmed: 22302738
J Leukoc Biol. 2018 Jul;104(1):21-29
pubmed: 29345367
Nat Rev Drug Discov. 2022 Aug;21(8):601-620
pubmed: 35650427
Nat Rev Nephrol. 2016 Jun;12(6):325-38
pubmed: 27108839
Sci Rep. 2017 Aug 2;7(1):7117
pubmed: 28769105
J Immunol. 2005 Dec 15;175(12):7989-95
pubmed: 16339535
J Immunol. 2008 Sep 15;181(6):4004-9
pubmed: 18768855
Nat Rev Immunol. 2013 Jan;13(1):9-22
pubmed: 23154224
Genome Biol. 2014;15(12):550
pubmed: 25516281
Blood. 2014 May 15;123(20):e110-22
pubmed: 24695852
Infect Immun. 2016 May 24;84(6):1753-1760
pubmed: 27021243
Nat Rev Cancer. 2020 Oct;20(10):594-607
pubmed: 32678342
Curr Opin Immunol. 2010 Dec;22(6):740-6
pubmed: 21030229
Sci Data. 2018 Dec 04;5:180275
pubmed: 30512017
J Immunol. 2014 May 15;192(10):4852-8
pubmed: 24740500
Allergy. 2014 Jun;69(6):719-29
pubmed: 24735452
Blood. 2013 Mar 14;121(11):1951-60
pubmed: 23293083
Cancer Res. 2021 Nov 1;81(21):5555-5571
pubmed: 34429328
Clin Exp Allergy. 2010 Apr;40(4):563-75
pubmed: 20447076
Immunity. 2007 Dec;27(6):952-64
pubmed: 18093541
Genomics. 2006 Aug;88(2):133-42
pubmed: 16698233
Proc Natl Acad Sci U S A. 2008 May 20;105(20):7240-5
pubmed: 18480254
Cell. 2010 Mar 5;140(5):619-30
pubmed: 20211132
Mol Cell Biol. 2001 Apr;21(8):2716-25
pubmed: 11283251
Immunol Rev. 2001 Feb;179:173-81
pubmed: 11292021
Bioinformatics. 2009 May 1;25(9):1105-11
pubmed: 19289445
J Immunol. 2002 Feb 15;168(4):1968-77
pubmed: 11823533
Front Immunol. 2011 Nov 08;2:57
pubmed: 22566847
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Immunol Rev. 2010 May;235(1):172-89
pubmed: 20536563
Science. 2017 Jun 9;356(6342):1072-1076
pubmed: 28495875
Nat Rev Immunol. 2017 May;17(5):333-340
pubmed: 28163302
Sci Rep. 2017 Jul 19;7(1):5922
pubmed: 28725048
Mucosal Immunol. 2017 Jan;10(1):172-183
pubmed: 27118491
JCI Insight. 2017 Dec 21;2(24):
pubmed: 29263310
Genome Biol. 2016 Apr 28;17:77
pubmed: 27121950
Front Immunol. 2020 Oct 15;11:580302
pubmed: 33178208
Blood. 2006 Mar 1;107(5):1996-2003
pubmed: 16254138
Cell Rep. 2021 Nov 2;37(5):109955
pubmed: 34731634
Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8708-13
pubmed: 26124135
Front Immunol. 2021 Dec 14;12:802839
pubmed: 34970274
Front Immunol. 2019 May 24;10:1084
pubmed: 31178859
J Exp Med. 2010 Aug 30;207(9):1807-17
pubmed: 20805564
J Clin Invest. 2011 Jul;121(7):2736-49
pubmed: 21670502